Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Invasive strategy shows no benefit in cardiovascular death reduction for older NSTEMI patients

An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined risk of cardiovascular death or MI, although non-fatal MIs and subsequent revascularisation procedures were reduced, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Study finds no added benefit of extensive ablation for persistent atrial fibrillation

In patients with persistent atrial fibrillation (AF), standard treatment with pulmonary vein isolation (PVI) ablation resulted in similar outcomes to more extensive ablation in other areas of the heart.

2 Sep 2024

Cryoballoon ablation as effective as radiofrequency for atrial fibrillation in heart failure patients

Cryoballoon (CB) ablation is as effective at reducing recurrences of atrial fibrillation (AF) and atrial tachycardia (AT) at 1-year, when compared to the current most widely used technique, radiofrequency (RF) ablation, in heart failure patients with a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug - 2 Sept).

2 Sep 2024

Catheter ablation proven effective for atrial fibrillation in new study

A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug - 2 Sept).

2 Sep 2024

Study finds wearable monitors effective in diagnosing atrial fibrillation

Wearable, long-term continuous heart monitors helped identify 52% more cases of atrial fibrillation compared to usual care, but that did not lead to a reduction in hospitalizations due to stroke, according to a study led by the Duke Clinical Research Institute.

1 Sep 2024

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Study links blood markers to long-term cardiovascular risk in women

Research supported by the National Institutes of Health has found that measuring two types of fat in the bloodstream along with C-reactive protein (CRP), a marker of inflammation, can predict a woman's risk for cardiovascular disease decades later.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

Evening versus morning dosing of antihypertensive medications provides no added benefits

In two trials, one in frail elderly patients, evening administration of blood pressure (BP)-lowering medications had no clinical benefits over morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Timing of blood pressure medication administration does not affect outcomes

Evening administration of blood pressure (BP)-lowering medications did not reduce the risk of cardiovascular events or death compared with morning administration, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

MATTERHORN trial finds TEER non-inferior to surgery for secondary mitral regurgitation

There was no difference in efficacy between transcatheter edge-to-edge repair (TEER) and surgery in patients with secondary mitral regurgitation (MR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Research suggests flexible approach to antiplatelet management after drug-eluting stent implantation

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting stent (DES) implantation, there was no difference with respect to ischaemic outcomes or major bleeding between perioperative aspirin monotherapy and receiving no antiplatelet therapy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

TAVI patients show no benefit from continuing oral anticoagulants

There was no apparent benefit to continuing oral anticoagulants compared with interruption in patients undergoing transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Interrupting beta-blockers after myocardial infarction shows no advantage

The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction (MI) and there was no benefit to the patients' quality of life, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

New ESC guidelines introduce intensive blood pressure targets and renal denervation recommendations

Updated ESC Guidelines on the management of elevated blood pressure and hypertension include a new elevated blood pressure category, more ambitious and intensive treatment targets, and, for the first time, recommendations on the use of renal denervation to treat various forms of hypertension.

30 Aug 2024

Updated atrial fibrillation guidelines focus on risk management and patient-centered care

The 2024 ESC Guidelines for the management of atrial fibrillation, developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), contain a number of new approaches and treatment-specific recommendations to help manage the surging numbers of patients with AF worldwide.

30 Aug 2024

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

There was no difference in major post-operative complications in patients who continued vs. stopped renin-angiotensin system inhibitors (RASIs) before non-cardiac surgery, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Low lipoprotein (a) levels do not cause type 2 diabetes, research shows

New research has shown that, contrary to some previous studies, low levels of lipoprotein (a) – a parcel of fats and protein in the blood – do not cause type 2 diabetes.

29 Aug 2024

Previous
1
...
89
90
91
92
93
94
95
...
1049
Next

Stroke News and Research

Further Reading

Invasive strategy shows no benefit in cardiovascular death reduction for older NSTEMI patients

Study finds no added benefit of extensive ablation for persistent atrial fibrillation

Cryoballoon ablation as effective as radiofrequency for atrial fibrillation in heart failure patients

Catheter ablation proven effective for atrial fibrillation in new study

Study finds wearable monitors effective in diagnosing atrial fibrillation

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Study links blood markers to long-term cardiovascular risk in women

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

Evening versus morning dosing of antihypertensive medications provides no added benefits

Timing of blood pressure medication administration does not affect outcomes

MATTERHORN trial finds TEER non-inferior to surgery for secondary mitral regurgitation

Research suggests flexible approach to antiplatelet management after drug-eluting stent implantation

TAVI outperforms surgery in reducing complications for women with severe aortic stenosis

TAVI patients show no benefit from continuing oral anticoagulants

Interrupting beta-blockers after myocardial infarction shows no advantage

New ESC guidelines introduce intensive blood pressure targets and renal denervation recommendations

Updated atrial fibrillation guidelines focus on risk management and patient-centered care

Major surgery complications unaffected by use of renin-angiotensin system inhibitors

Low lipoprotein (a) levels do not cause type 2 diabetes, research shows

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News